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Abstract
Low-frequency ultrasound presents an attractive method for transdermal drug delivery. The 
controlled, yet nonspecific nature of enhancement broadens the range of therapeutics that can be 
delivered, while minimizing necessary reformulation efforts for differing compounds. Long and 
inconsistent treatment times, however, have partially limited the attractiveness of this method. 
Building on recent advances made in this area, the simultaneous use of low- and high-frequency 
ultrasound is explored in a physiologically relevant experimental setup to enable the translation of 
this treatment to testing in vivo. Dual-frequency ultrasound, utilizing 20 kHz and 1 MHz 
wavelengths simultaneously, was found to significantly enhance the size of localized transport 
regions (LTRs) in both in vitro and in vivo models while decreasing the necessary treatment time 
compared to 20 kHz alone. Additionally, LTRs generated by treatment with 20 kHz + 1 MHz were 
found to be more permeable than those generated with 20 kHz alone. This was further 
corroborated with pore-size estimates utilizing hindered-transport theory, in which the pores in 
skin treated with 20 kHz + 1 MHz were calculated to be significantly larger than the pores in skin 
treated with 20 kHz alone. This demonstrates for the first time that LTRs generated with 20 kHz 
+ 1 MHz are also more permeable than those generated with 20 kHz alone, which could broaden 
the range of therapeutics and doses administered transdermally. With regard to safety, treatment 
with 20 kHz + 1 MHz both in vitro and in vivo appeared to result in no greater skin disruption than 
that observed in skin treated with 20 kHz alone, an FDA-approved modality. This study 
demonstrates that dual-frequency ultrasound is more efficient and effective than single-frequency 
ultrasound and is well-tolerated in vivo.
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1. Introduction
Non-invasive transdermal drug delivery (TDD) presents an attractive method for drug 
administration [1,2]. In addition to the potential benefits of patient compliance associated 
with painless drug delivery, TDD can reduce first-pass degradation of drugs typically 
associated with the oral route and enables the delivery of larger molecules limited to 
subcutaneous injection [1,2]. Despite countless experimental investigations surrounding this 
route, its use clinically is largely limited to the delivery of small molecules, such as nicotine 
and estradiol [3]. This is due in large part to the barrier posed by the outermost layer of the 
skin, the stratum corneum (SC). While there exist several methods to overcome or 
permeabilize this membrane, each method has associated limitations [4]. Treatment of skin 
with ultrasound (US) (also known as sonophoresis), for example, has the potential to 
permeabilize relatively large areas, but typically requires large, bulky equipment and a 
power source [5]. Recently, there has been renewed research interest in sonophoresis. Two 
major challenges limiting greater clinical use is the portability of the equipment required and 
the length of the treatment required [6,7]. Studies addressing the former hurdle have focused 
on the use of low-profile cymbal transducer arrays that can be integrated into patches [8,9]. 
In addition to portability, these devices minimize the excitation voltages required, reducing 
power consumption [10].
With regard to the treatment times necessary, a new approach has recently been investigated 
to increase permeabilization efficiency, thereby decreasing the required treatment time [11]. 
This method employs the use of two US frequencies simultaneously. A proof-of-concept 
study demonstrated that the use of both low- (<60 kHz) and high-frequency (>1 MHz) US 
together resulted in greater transient cavitation events, as assessed by pitting data, and 
resulted in larger localized transport regions (LTRs) in vitro [11].
While this initial study demonstrated that the simultaneous application of low- and high-
frequency US could enhance cavitational activity, the experimental setup required 
submerging tissue in a tank to allow for both frequencies to be applied simultaneously. This 
setup could result in artificial enhancement in skin permeability due to the underside of the 
dermatomed skin layer (epidermis) being exposed to surfactant present in the coupling 
solution. Additionally, there has never been a mechanistic exploration of the permeability of 
the resulting LTRs or the safety and tolerability of this new method. Here, we build on this 
preliminary report of the use of dual-frequency US to first develop an experimental setup 
which exposes only the top surface of the skin to the coupling solution, while allowing for 
the simultaneous application of both 20 kHz and 1 MHz US. We then use this setup to 
explore LTR formation, investigate the mechanistic underpinnings of this modality, and 
quantify the resulting permeability of treated skin in vitro over a range of relevant treatment 
times. We also examine treated skin histologically to determine the level of barrier 
disruption as a result of the US treatment. Finally, we utilize this setup to allow for treatment 
in vivo in pigs to examine LTR formation and tolerability.
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2. Experimental section
2.1. Materials
All chemicals were used as received. Sodium lauryl sulfate (SLS), 4 kDa FITC-labeled 
dextran, and phosphate buffered saline (PBS) were obtained from Sigma-Aldrich Company 
(St. Louis, MO). Lysine-fixable 3, 10, and 70 kDa dextrans labeled with Texas Red were 
purchased from Invitrogen (Carlsbad, CA). Allura red was obtained from TCI America 
(Portland, OR).
2.2. Preparation of skin samples and ultrasonic treatment
All procedures were approved by the Massachusetts Institute of Technology Committee on 
Animal Care. Porcine skin was used because of its physiological similarity to human skin 
[12]. Skin was procured by Research 87 (Boylston, MA). The preparation and storage of 
skin samples followed previously published protocols [13]. Briefly, back and flank skin was 
dissected from female Yorkshire pigs within an hour of euthanization. This skin was 
sectioned into 25-mm wide strips and the subcutaneous fat was removed using a razor blade. 
The skin was then stored at−85 °C for up to six months. Prior to use in experiments, skin 
was thawed for 20 min in PBS and the hair was trimmed using surgical scissors. The skin 
was then dermatomed to 700 µm using an electric reciprocating dermatome (Zimmer 
Orthopedic Surgical Products, Dover, Ohio), and cut into 25 × 25-mm samples. The skin 
samples were then mounted in a custom diffusion cell to enable simultaneous sonication of 
the skin with both 20 kHz and 1 MHz US. Specifically, high vacuum grease (Dow Corning, 
Midland, MI) was applied to the flange of the custom-built top (FineLine Prototyping, 
Raleigh, NC) and 15-mm inner-diameter diffusion cell receiver chamber (PermeGear, 
Hellertown, PA). The skin was applied to the custom-designed top and then sandwiched 
between the top and receiver chamber. The top and bottom chambers were then clamped 
together and the receiver chamber was filled with PBS (12 mL) and a small volume of PBS 
was added to the custom-designed top to keep the skin hydrated until treatment.
Skin samples were treated in a similar fashion to previously reported methods [11,14,15]. 
Specifically, a 20 kHz horn (Sonics and Materials, Inc. Model VCX 500, Newtown, CT) and 
a 1 MHz horn (Therasound 3 Series, Richmar Corporation, Chattanooga, TN) were 
employed. The 20 kHz US horn was positioned 3 mm above the skin surface and operated at 
an intensity of 8 W/cm2 (by calorimetry) and a 50% duty cycle (1 s on, 1 s off). The 1 MHz 
horn was placed on the side of the 20 kHz horn, approximately 5 cm from the leading edge 
of the skin. The 1 MHz horn was programmed to operate at a power of 2.0 W/cm2 
continuously. The custom diffusion top was filled with 300 mL of a solution of 1 wt.% SLS 
and 0.04 wt.% Allura red dye in PBS. The treatment times tested ranged between 4 and 8 
min, which are within the range of commonly-tested treatment times in the literature 
[16,17]. Thermal effects were determined to be negligible as the temperature increase of the 
coupling solution was less than 2 °C even at the longest treatment time considered. Prior 
work has shown that an increase of at least 10 °C is necessary to appreciably permeabilize 
the skin [18]. Treatments utilizing 20 kHz US alone were used as a control throughout the 
study. The use of 1 MHz US alone was not tested because it has been established in the 
literature that high-frequency US (≥1 MHz) at typical intensities, such as those used here, do 
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not generate transient cavitation [1]. As a result, there would not be any quantifiable LTR 
formation and the resulting flux of 4 kDa dextran would not be significantly different than 
that observed in native skin [18].
2.3. Skin resistivity measurements
Electrical resistivity has previously been shown to be an accurate measure of skin 
perturbation [15,19]. The resistivity across skin samples was determined using a method 
similar to previously published protocols [17,20]. Specifically, a 10 Hz sinusoidal wave with 
root-mean-square voltage of 100 mV was employed (Hewlett Packard Model 33120A, Palo 
Alto, CA). This signal was then applied across the skin using two Ag/AgCl electrodes (In 
Vivo Metric, Healdsburg, CA). The resulting current was measured using a multimeter 
(Fluke, Model 87 V, Everett, WA) and the resistance calculated using Ohm's Law. Finally, 
the resistivity was found by multiplying the resistance by the area of the skin exposed (the 
diffusion cells have an exposure area of 1.76 cm2). In all measurements, the background 
resistance (resistance of PBS in the diffusion cell without skin) was accounted for by 
subtracting it from the resistance observed when the skin was mounted in the diffusion cell. 
All skin samples were ensured to have a starting resistivity of at least 35 k Ω·cm2, otherwise, 
the skin sample was considered damaged and discarded [19].
2.4. Quantification of LTR area
Immediately after the US treatment, the coupling solution was discarded and the diffusion 
top and skin were washed thoroughly with PBS to remove any remaining coupling solution. 
The diffusion cell was then disassembled, the skin removed and placed on a paper towel, and 
blotted dry to prepare it for imaging. The skin was imaged using a digital camera (Panasonic 
DMC-ZS7, 12.1 megapixels, shutter speed 1/2000 s) positioned approximately 10 cm above 
the skin. The resulting image was then cropped making sure that only the portion of the skin 
exposed to US was captured (1.5 cm × 1.5 cm) and processed using ImageJ 1.46r (National 
Institutes of Health, Bethesda, MD). Specifically, the blue channel of the LTR image was 
isolated because it has been shown to give the best contrast between LTRs and non-LTRs 
[21]. The image was then inverted, and the average pixel intensity of non-LTRs was 
measured. This pixel intensity was subtracted from the entire image to account for variations 
in lighting at the time of imaging. The image was then re-inverted. The threshold was 
adjusted using the default value found by ImageJ. Finally, the LTR area was quantified using 
the “Analyze Particles” function.
2.5. Steady-state dextran permeability
Once the skin samples were imaged to quantify LTR size, they were remounted in clean 
diffusion cells using standard glass tops (PermeGear, Hellertown, PA), and filled with PBS. 
A magnetic stir bar was added to the receiver chamber. The donor chambers were filled with 
1.5 mL of 0.1 wt.% 4 kDa dextran in PBS. The receiver chambers were magnetically stirred 
at 500 rpm. To ensure that the lag-phase was overcome, the receiver chambers were sampled 
between hours 20 and 48. For each sample, a 200 µL aliquot was taken and replaced with an 
equal volume of fresh PBS. These samples were then placed in 96-well plates and read using 
a plate reader (Tecan Infinite M200Pro) (excitation: 490 nm, emission: 525 nm). A known 
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standard concentration series was also run to convert the sample emission to concentration. 
The permeability, P of dextran was then calculated using Eq. (1):
(1)
where VR is the volume of the receiver chamber, A is the area for diffusion, CD is the 
concentration of dextran in the donor chamber, and ΔCR/Δt is the regression slope of a plot 
of the receiver chamber concentration with time.
2.6. Aqueous porous pathway model
Theoretical pore sizes were estimated using the aqueous porous pathway model [22]. This 
theory allows for the estimation of theoretical pores in a medium using the permeability of a 
molecule (calculated from Eq. (1)) and the electrical resistivity of the membrane upon the 
application of a current. Assuming that both the permeant and the ions traverse the same 
pathway through the skin, a hindrance factor may be calculated for the permeant from 
known relations [23].
The permeability (P) and electrical resistivity (R) are related by Eq. (2):
(2)
where C is a constant given by:
(3)
In Eq. (3), k is the Boltzmann's constant, T is the absolute temperature, z is the valence of 
the electrolyte, F is the Faraday's constant, cion is the molar concentration of the electrolyte, 
e is the electronic charge, D∞ is the diffusion coefficient of either the permeant or the ion at 
infinite dilution, λ is the ratio of the radius of either the permeant or the ion to the radius of 
the aqueous pores in the skin, and H(λ) is the hindrance factor for the permeant or the ion 
[22].
The relation for the hindrance factor is given by [24]:
(4)
Once C is determined from Eq. (2), the only unknown quantity present is the skin pore 
radius in the ratio of the hindrance factors in Eq. (3). It is important to note that there is an 
upper limit on the pore size that can be estimated using Eq. (4) based on the permeant 
selected. The permeant must experience some amount of hindrance as a result of traversing 
the pores. Because the hindrance factor ranges from 0 to 1 (1 representing no hindrance), an 
upper limit is set on H(λ), above which the pores are considered to be too large to estimate. 
Here, in this report, the upper limit on the hindrance factor is H(λ) = 0.9, which has been 
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used previously in the literature [22,23]. The hydrodynamic radius of 4 kDa dextran is 14 Å. 
This yields an upper limit on pore size estimates of approximately 870 Å [25]. Finally, the 
applicability of this theory to pore size estimates in skin has previously been tested by 
plotting log(P) versus log(R) and requiring that the 95% confidence interval of the 
regression slope contains the theoretical value of −1 (see Eq. (2)). Previous work has shown 
this requirement to hold, and here too, it was ensured that the 95% confidence interval of the 
regression slope contained the value of −1 [15].
2.7. Histology
Individual skin samples were either treated with 20 kHz alone or with 20 kHz + 1 MHz as 
described in Section 2.2. After treatment, these samples were removed from the diffusion 
cell, washed, and blotted dry. The area exposed to the coupling solution and the US was 
isolated using a scalpel. The treated area was then sliced into 2 mm-wide sections and fixed 
overnight in 10% formalin. The skin sections were then mounted in paraffin blocks to allow 
cross sections of the skin to be taken. Two, 8 µm-thick sections separated by a 200 µm step 
were stained with hematoxylin and eosin and mounted to glass microscope slides for 
histological examination.
2.8. Dextran diffusion depth
While the US treatment increases the permeability of the skin, there may still exist 
limitations on the molecular weight of molecules that can diffuse through treated skin. To 
better understand this size-dependent permeability, dextrans of various sizes labeled with 
Texas red were allowed to diffuse through treated skin for a set period of time. Specifically, 
3, 10, and 70 kDa dextrans labeled with Texas Red were used to image the relative 
penetration depth of these molecules into the skin. Skin was treated as described in Section 
2.2 for 6 or 8 min. Additionally, untreated skin samples were included as a control. After 
treatment, the skin samples were mounted in fresh diffusion cells with a magnetic stir bar in 
the receiver chamber. Only one molecule was allowed to diffuse through any given skin 
sample. 1-mL of 3, 10, or 70 kDa dextran solution at a concentration of 1 mg/mL in PBS 
was added to the donor chamber and the receiver chamber was stirred at 500 rpm. The dye 
was allowed to diffuse for only 1 h to ensure that the diffusion front would not reach the 
receiver chamber. At that point, the dye solution was removed and the skin thoroughly 
washed with PBS. The skin was then sectioned and fixed overnight in 10% formalin. 
Mounting and processing was performed as described in Section 2.7 with the exception that 
the skin was unstained.
The slides were imaged by the microscopy core facility in the Swanson Biotechnology 
Center (Massachusetts Institute of Technology). Briefly, slides were imaged with an 
Olympus FV-1000MP multiphoton microscope with a 25×, 1.05 N.A. objective. Samples 
were excited at 860 nm using a Ti-Sapphire pulsed laser (Spectra-Physics, Santa Clara, CA). 
Emission for Texas red was collected with a 607/70 nm band-pass filter and collagen was 
imaged by second harmonic generation at 430 nm. Individual image channels were 
combined in ImageJ.
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2.9. In vivo experiments
All procedures were conducted in accordance with the protocols approved by the 
Massachusetts Institute of Technology Committee on Animal Care. Female Yorkshire pigs 
approximately 50 kg in size were used for in vivo testing. Anesthesia was induced with 
intramuscular injection of 5 mg/kg Telazol and 2 mg/kg xylazine. A 20 gauge peripheral 
venous catheter was then placed in a vein in the ear of the animals. Anesthesia was 
maintained with 1 mg/kg ketamine and 0.3 mg/kg midazolam intravenously. The animals 
were laid on their side. The hair on the flank of the animal was carefully trimmed away 
using surgical scissors so as to not damage the skin. The custom-built top was then affixed to 
the skin using high vacuum grease. Treatment was performed following methods described 
in Section 2.2 with the addition of a plastic spacer connecting the diffusion top to the 20 kHz 
horn to maintain a distance of 3 mm from the horn tip to the skin. In this manner, position 
variability due to breathing of the animal is minimized. Six and eight minute treatments 
were tested.
Following treatment, the diffusion top was removed and the skin washed with water to 
remove any excess coupling solution and gently blotted dry. The resulting LTRs were 
imaged and quantified according to the procedure described in Section 2.4. Once the LTRs 
were imaged, a biopsy was taken for the purpose of histological examination using a punch 
biopsy with a 3 mm diameter (Miltex, York, PA). The biopsies were fixed in 10% formalin. 
Histological slides were prepared as described in Section 2.7.
2.10. Statistical significance
Statistical significance was defined throughout as P < 0.05. P-values were determined by 
one-way analysis-of-variance with multiple comparison testing unless otherwise noted. All 
calculations were performed in MatLab R2014a (MathWorks, Natick, MA).
3. Results and discussion
3.1. In vitro results
To better understand enhancement in skin permeability as a result of the simultaneous use of 
20 kHz + 1 MHz US, a more relevant experimental setup had to be designed to allow for the 
simultaneous application of both low- and high-frequency US. A custom-built top was 
designed in AutoCAD 2012 (see Fig. 1A).
The top was designed so as to allow for unhindered bubble nucleation over the skin by the 1 
MHz US horn. It was found that the top allowed for bubbles nucleated by the 1 MHz horn to 
oscillate over the area of the skin (Fig. 1B).
Once the top was determined not to hinder bubble formation by the 1 MHz horn, porcine 
skin samples were treated in vitro with the diffusion top and the resulting LTR areas 
quantified. LTR sizes as a result of either 20 kHz or 20 kHz + 1 MHz US are shown in Fig. 
2A.
As shown in Fig. 2A, a 2.5-fold and nearly 6-fold enhancement in LTR size was observed at 
treatment times of 6 and 8 min, respectively, using both US frequencies simultaneously (P < 
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0.0043). No significant difference in LTR size was observed at the shortest treatment time. 
Additionally, no significant difference was found between LTR sizes at any treatment time 
using 20 kHz US alone. This is in clear contrast to what was found using 20 kHz + 1 MHz, 
in which there is a statistically significant increase in LTR size with increasing treatment 
time (P < 0.048). In this new study, longer treatment times were required compared to the 
previously published report. This is a result of the experimental setup that was employed in 
the preliminary report [11]. Specifically, that study employed a tank to allow for skin 
samples to be exposed to 20 kHz and 1 MHz simultaneously. While treatment utilizing 20 
kHz alone was included as a control in that study to validate the phenomenon of enhanced 
cavitational activity using dual-frequency US, submersion of skin samples in the tank 
exposed the underlying epidermis to the coupling fluid containing SLS [11]. This results in 
additional permeabilization of the skin. Therefore, in this present study, the treatment times 
examined were increased by 2 min. The setup reported here is a more physiologically 
relevant setup and now allows for testing of dual-frequency US in vivo, which was not 
previously possible. Aside from the increased treatment time required in this study, the 
general trend of LTR enhancement as a result of treatment with 20 kHz + 1 MHz compared 
to 20 kHz alone is in good agreement with that presented previously [11].
Next, the flux of 4 kDa dextran and theoretical pore sizes of treated skin were determined 
for treatment times of 6 and 8 min. Fluxes are shown in Fig. 2B and pore sizes in Table 1.
A statistically significant increase in the flux of 4 kDa dextran was observed by using 20 
kHz + 1 MHz as opposed to 20 kHz alone (P = 0.0012 and 1.25 × 10−6 for 6 and 8 min 
treatments, respectively). Again, there was a statistical difference between the flux observed 
for samples treated with 20 kHz + 1 MHz for 6 or 8 min (P = 0.009), but no increase in flux 
with treatment time for the use of 20 kHz alone. Interestingly, the enhancement in flux at 
both treatment times using 20 kHz + 1 MHz was greater than that which would be expected 
based on the increase in LTR sizes alone at each treatment time. The dextran flux was 3.5- 
and 7.1-fold greater using 20 kHz + 1 MHz at 6 and 8 min, respectively, compared to the use 
of 20 kHz alone, while LTR area increased 2.5- and 6-folds respectively. Specifically, 
regression slope analysis of plots of permeability (from Eq. (1)) vs. LTR area demonstrated a 
greater increase in permeability per increase in LTR area through the use of 20 kHz + 1 
MHz at both six and eight minute treatment times. Moreover, at each treatment time, the 
95% confidence interval of the regression slopes does not overlap. This would suggest that 
LTRs generated by 20 kHz + 1 MHz are more permeable than those generated with 20 kHz 
alone.
This result is further supported by the pore size estimates utilizing the aqueous porous 
pathway model (Table 1). While the average theoretical pore size generated in samples 
treated with 20 kHz US was less than 81 Å, even the lower estimate of the pore sizes 
generated in samples treated with 20 kHz + 1 MHz was larger than the limit of detection 
(870 Å). These theoretical pore sizes can be attributed to the LTRs because the pore sizes of 
non-LTRs have previously been shown to be nearly identical to those found in untreated skin 
[23]. Because this previous result was found using a smaller permeant (calcein), a larger 
distribution of skin pores could be sampled by the permeant (on account of its smaller size), 
which would result in larger pore size estimates. As a result, it is reasonable to assume that 
Schoellhammer et al. Page 8
J Control Release. Author manuscript; available in PMC 2016 April 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the majority of the 4 kDa dextran would diffuse through the LTRs and therefore, the pore 
sizes calculated would more greatly reflect pore sizes within the LTRs. Further, there was no 
statistical difference between the pore sizes found as a result of six or eight minute 
treatments with 20 kHz alone (two-tailed Student's T-test).
The finding that the enhancement in permeability is greater than that observed in LTR size is 
a new and surprising result not previously explored using steady-state permeation studies. 
Indeed, the opposite result was previously reported, demonstrating a greater enhancement in 
LTR formation than in the delivery of model permeants [11]. This previous finding was 
hypothesized to be a result of larger molecules only having the capacity to “sample” pores 
large enough to diffuse through, with 20 kHz + 1 MHz treatment having no effect on the size 
of pores generated in the skin. This finding could potentially have been due to the artificial 
enhancement in permeability stemming from the experimental setup employed masking the 
true enhancement in permeability gained through the use of 20 kHz + 1 MHz US. 
Regardless of the reason, the data reported here unequivocally demonstrate that treatment 
with 20 kHz + 1 MHz does in fact increase pore size, resulting in a greater enhancement in 
permeability than in LTR size.
Further exploring the increase in pore size as a result of treatment with 20 kHz + 1 MHz US, 
the diffusion of 3, 10, and 70 kDa dextran labeled with Texas red was visualized by 
microscopy (Supplementary Fig. 1). Qualitatively, examination of skin samples treated with 
20 kHz + 1 MHz showed greater penetration of 3, 10, and even 70 kDa dextran compared to 
skin treated with 20 kHz alone. As expected, there was negligible penetration of any 
molecule into untreated skin. Discernable diffusion of macromolecules into skin in a 
relatively short diffusion time is exciting and could potentially allow for a broader range of 
therapeutics to be administered transdermally.
In addition to the permeability enhancement capabilities of the simultaneous use of 20 kHz 
+ 1 MHz US, the safety of this method was also assessed through histological examination 
of treated skin. All histology samples were examined by a pathologist in a blinded fashion to 
assess the location, extent, and severity of any disruption to normal tissue architecture. 
Representative skin histology images are shown in Fig. 3.
As expected, histological damage was noted to scale with treatment time regardless of the 
frequencies employed. Ablation of the SC was noted in all samples in discrete, sporadic 
areas. At treatment times of 6 and 8 min, there were ablative effects noted in the viable 
epidermis, and superficial dermis in a localized manner. This was determined by the 
observation of minor coagulation of collagen in the superficial layer of the dermis making 
distinction of individual fibers impossible. This was observed in both samples treated with 
20 kHz and 20 kHz + 1 MHz US. Further, samples treated for 6 and 8 min showed evidence 
of vacuole formation in the epidermis and dermis and minor coagulative necrosis was 
observed sporadically throughout the dermis. These observations have previously been noted 
in the literature [26]. Importantly, there was no quantifiable difference in the extent or 
severity of tissue disruption between samples treated with 20 kHz and those treated with 20 
kHz + 1 MHz at each treatment time considered. The fact that 20 kHz + 1 MHz US results 
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in similar skin disruption as that resulting from treatment with 20 kHz alone, is reassuring, 
considering that the latter is an FDA-approved modality for the delivery of lidocaine [27].
3.2. In vivo results
Based on the significant enhancement observed at treatment times of 6 and 8 min in vitro 
and the likely safety of this method, this new treatment regimen was translated to in vivo 
testing in Yorkshire pigs. LTR formation and histological examination were performed to 
ascertain if the enhancement observed in vitro would persist in an in vivo system. The sizes 
of LTRs as a result of treatment are shown in Fig. 4.
The trends in LTR formation observed in vivo are in good agreement with those found in 
vitro. Treatment with 20 kHz + 1 MHz US resulted in statistically larger LTRs compared to 
those generated with the use of 20 kHz alone at both treatment times tested (P ≤ 0.032). 
Moreover, similar to the in vitro results, the size of LTRs generated with 20 kHz US alone at 
6 and 8 min was not statistically different (P = 0.73). Additionally, LTR formation using 20 
kHz + 1 MHz US for 6 min was again larger, on average, than that resulting from 8 min of 
treatment using 20 kHz alone. This further confirms the fact that 20 kHz + 1 MHz US 
enables the reduction of treatment times to achieve comparable LTR sizes. Reducing the 
required treatment time will make US-assisted transdermal drug delivery more convenient, 
potentially enabling broader clinical use.
Clinical monitoring of the pigs over the period of a week post treatment showed the animals 
to be free of distress. Further, the area of the skin that was treated appeared healthy and 
uninfected. The treated area was undistinguishable from the surrounding tissue within four 
days posttreatment and identification of the treated area at earlier times posttreatment was 
only possible because of the presence of the Allura red dye staining the LTRs (see Fig. 5). 
Histological examination of the skin demonstrated sporadic ablation of the SC, epidermis 
and dermis in addition to minor vacuole formation and coagulative necrosis sporadically 
thought the upper layers of the dermis (see Fig. 6). The extent of skin injury was comparable 
to that observed in tissue treated in vitro. Finally, the extent and severity of tissue injury 
again could not be differentiated between those samples treated with 20 kHz or 20 kHz + 1 
MHz US. Based on histological examination, treatments should likely be less than 8 min so 
that the treatment minimizes disruption to the dermis.
One interesting feature noted during histological examination of the tissue was the pattern of 
tissue ablation observed in skin samples treated with 20 kHz + 1 MHz US. As it can be seen 
in Fig. 6, portions of viable epidermis appear to have been ablated without ablation of the 
SC in samples treated with 20 kHz + 1 MHz US. This might suggest that transient cavitation 
is occurring within the skin. Cavitation within the skin has previously been hypothesized to 
play a significant role in low-frequency US and high-frequency US has been shown to 
produce stable cavitation within the skin [18,28]. Perhaps, under the influence of the 20 kHz 
horn, cavitation bubbles within the skin are now growing to unstable sizes, resulting in 
transient cavitation within the skin. This would be an interesting new area of study and 
would present a new phenomenon in US-mediated transdermal drug delivery.
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4. Conclusions
This study investigated the simultaneous use of 20 kHz + 1 MHz US for the purpose of 
transdermal drug delivery in vitro and in vivo in Yorkshire pigs. LTR formation as a result of 
20 kHz + 1 MHz was found to be enhanced compared to 20 kHz alone at treatment times of 
6 and 8 min. It was further found that utilizing 20 kHz + 1 MHz could decrease the required 
treatment time to achieve a certain LTR size. Additionally, LTRs formed as a result of 
treatment with 20 kHz + 1 MHz US were found to be more permeable than those formed 
with 20 kHz US alone. This was hypothesized to be due to enhanced cavitational activity, 
resulting in the estimation of larger pore sizes present in skin treated with 20 kHz + 1 MHz 
utilizing hindered-transport theory. Despite this greater permeability, histological 
examination of skin treated with 20 kHz + 1 MHz US in vitro and in vivo showed no greater 
disruption of viable tissues compared to the use of 20 kHz US alone, an FDA approved 
modality. Animals treated with 20 kHz + 1 MHz showed no clinical signs of distress and the 
treated area remained free of infection. The significant improvement in performance 
utilizing dual-frequency US should motivate further investigation into this method.
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Fig. 1. 
A) Custom designed diffusion top used for the study to allow for the simultaneous 
application of the 20 kHz and 1 MHz US horns. B) View from below the diffusion top 
looking up through the opening where the skin is normally mounted showing significant 
bubble formation when the 1 MHz US horn is on. The diffusion top is filled with a coupling 
solution of 1 wt.% SLS and 0.04 wt.% Allura red in PBS.
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Fig. 2. 
A) In vitro LTR size vs. treatment time as a result of treatment with either 20 kHz or 20 kHz 
+ 1 MHz US. Each point represents n ≥ 3 biological repeats. Averages and standard 
deviations are presented. B) Flux of 4 kDa dextran at steady-state as a result of the US 
treatment for either 6 or 8 min. The median, 25th, and 75th percentiles are shown. Whiskers 
indicate the most extreme data points. Each condition represents n ≥ 5 biological repeats.
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Fig. 3. 
Representative images of the histological view of in vitro-treated porcine skin. Skin that was 
dermatomed and then immediately fixed in formalin is shown as the control. The scale bar in 
all images is 50 µm.
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Fig. 4. 
In vivo LTR sizes as a result of treatment with either 20 kHz US or 20 kHz + 1 MHz US. 
Each condition represents n = 4 biological repeats. Averages and standard deviations are 
presented.
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Fig. 5. 
Images of the sites of the US treatment in vivo over time. Images on Day 0 were taken 
immediately after the US treatment. Image brightness has been adjusted to account for 
differences in lighting on subsequent days. Each image is 15 × 15 mm.
Schoellhammer et al. Page 18
J Control Release. Author manuscript; available in PMC 2016 April 08.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 6. 
Representative images of the histological view of in vivo-treated porcine skin. The scale bar 
in all images is 100 µm.
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